The BareStory
On Friday, January 23, 2026, President Donald Trump delivered a pre-recorded address to the annual March for Life in Washington, D.C., characterizing the movement to protect the unborn as a "battle that must be won." In his remarks, the president highlighted the overturning of *Roe v. Wade* as evidence of progress and stated that his administration is actively working to foster a culture that supports life and religious liberty.
The event, which also featured scheduled appearances by Vice President JD Vance and House Speaker Mike Johnson, took place amid renewed pressure on federal health agencies regarding abortion access. Leading up to the march, the pro-life organization Live Action sent a letter to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Dr. Marty Makary. The group demanded the suspension of the abortion drug mifepristone’s approval, calling for an end to mail and telehealth distribution and a reinstatement of stricter adverse-event reporting.
Live Action founder Lila Rose alleged in the letter that the drug’s approval process had been politically accelerated without adequate regard for patient safety. The group also released a video purporting to show clinics bypassing safety protocols, such as ultrasounds and follow-up visits.
In response, Planned Parenthood rejected the accusations, describing them as disinformation. Danika Severino, a vice president at the organization, stated that mifepristone is legal and safe, citing its use by over 7.5 million people over 25 years. An HHS spokesperson confirmed that officials are studying adverse event reports to assess the FDA’s risk mitigation program, while maintaining that Commissioner Makary is upholding rigorous, science-based review standards. Currently, the FDA permits mifepristone to be prescribed via telehealth and distributed by mail.
How it may affect me
As a U.S. reader:
• Access to mifepristone through telehealth and mail delivery could be restricted if the FDA yields to activist demands to suspend the drug’s approval or modify distribution protocols.
• Healthcare providers may face stricter compliance and reporting requirements as HHS officials study adverse event reports to evaluate the current risk mitigation program for abortion medication.
• The administration’s declared commitment to "protecting the unborn" suggests that federal policy will likely continue to target abortion availability and promote religious liberty in the near term.
